奧貝膽酸由美國Intercept制藥公司研發(fā)成功，是二十年來*研發(fā)用于治療膽汁淤積性肝病的藥物。奧貝膽酸屬法尼醇X受體激動(dòng)劑，通過活化法尼醇X受體，間接抑制細(xì)胞色素7A1（CYP7A1）的基因表達(dá)。由于CYP7A1是膽酸生物合成的限速酶，因此奧貝膽酸可以抑制膽酸合成，用于治療原發(fā)性膽汁性肝硬化和非酒精性脂肪性肝病。   

       深圳遠(yuǎn)揚(yáng)化學(xué)可提供奧貝膽酸申報(bào)所用全套雜質(zhì)， 隨貨附CoA證書，HNMR，MS，HPLC圖譜，純度符合申報(bào)要求，奧貝膽酸雜質(zhì)為我司優(yōu)勢(shì)雜質(zhì)，長期備有庫存，發(fā)貨快。如需奧貝膽酸雜質(zhì)相關(guān)詳細(xì)信息，歡迎我司業(yè)務(wù)人員獲取~

       除自主品牌雜質(zhì)對(duì)照品外，我司還代理英國NIBSC標(biāo)準(zhǔn)品，美國劍橋CIL同位素標(biāo)準(zhǔn)品，美國NIST標(biāo)準(zhǔn)物質(zhì)，歐洲標(biāo)準(zhǔn)局IRMM標(biāo)準(zhǔn)物質(zhì)，加拿大TRC標(biāo)準(zhǔn)品，TLC標(biāo)準(zhǔn)品，MOLCAN標(biāo)準(zhǔn)品，NRC標(biāo)準(zhǔn)品等，歡迎洽談。

附：奧貝膽酸雜質(zhì)庫存雜質(zhì)列表：

Obeticholic Acid

(4R)-4-((3R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 1

(R)-4-((3R,5S,6R,7S,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 2

(R)-4-((3R,5S,6S,7S,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 3

(R)-4-((3R,5S,6S,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 4

(R)-4-((3R,5S,6S,8S,9S,10S,13R,14S,17R)-6-ethyl-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 5

(4R)-4-((3R,5S,6R,7R,9S,10S,13R,14S,17R)-6-ethyl-3-(((R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)oxy)-7-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 6

(R)-4-((3R,5R,7S,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 7

(R)-4-((5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7-dioxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 8

(R)-methyl 4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate

Obeticholic Acid Impurity 9

(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 10

(R)-4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid

Obeticholic Acid Impurity 11

(R)-methyl 4-((3R,5S,6R,8S,9S,10S,13R,14S,17R)-6-ethyl-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate